BR112022007632A2 - Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer - Google Patents

Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer

Info

Publication number
BR112022007632A2
BR112022007632A2 BR112022007632A BR112022007632A BR112022007632A2 BR 112022007632 A2 BR112022007632 A2 BR 112022007632A2 BR 112022007632 A BR112022007632 A BR 112022007632A BR 112022007632 A BR112022007632 A BR 112022007632A BR 112022007632 A2 BR112022007632 A2 BR 112022007632A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
pharmaceutical composition
patient
methods
Prior art date
Application number
BR112022007632A
Other languages
English (en)
Portuguese (pt)
Inventor
Hayashi Shinko
Ishida Saori
Satoh Kazuki
Hata Masato
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112022007632A2 publication Critical patent/BR112022007632A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112022007632A 2019-10-25 2020-10-23 Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer BR112022007632A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019194717 2019-10-25
PCT/JP2020/039802 WO2021079958A1 (ja) 2019-10-25 2020-10-23 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ

Publications (1)

Publication Number Publication Date
BR112022007632A2 true BR112022007632A2 (pt) 2022-07-12

Family

ID=75620128

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007632A BR112022007632A2 (pt) 2019-10-25 2020-10-23 Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer

Country Status (9)

Country Link
US (1) US20240190961A1 (https=)
EP (1) EP4049675A4 (https=)
JP (1) JPWO2021079958A1 (https=)
KR (1) KR20220088425A (https=)
CN (1) CN114630679A (https=)
BR (1) BR112022007632A2 (https=)
CA (1) CA3155172A1 (https=)
TW (1) TWI887285B (https=)
WO (1) WO2021079958A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116547300B (zh) * 2021-09-30 2024-10-08 贝达药业股份有限公司 双特异性抗体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
ES2860952T3 (es) * 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
DK3354729T5 (da) * 2015-09-24 2024-09-30 Daiichi Sankyo Co Ltd Anti-garp-antistof
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
CN110049773A (zh) * 2016-07-14 2019-07-23 供石公司 TGFβ抗体、方法和用途
ES2863412T3 (es) * 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
PT3621694T (pt) * 2017-05-09 2023-10-09 Scholar Rock Inc Inibidores de lrrc33 e sua utilização
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp

Also Published As

Publication number Publication date
CA3155172A1 (en) 2021-04-29
TW202128761A (zh) 2021-08-01
KR20220088425A (ko) 2022-06-27
TWI887285B (zh) 2025-06-21
EP4049675A4 (en) 2023-11-22
JPWO2021079958A1 (https=) 2021-04-29
US20240190961A1 (en) 2024-06-13
EP4049675A1 (en) 2022-08-31
WO2021079958A1 (ja) 2021-04-29
CN114630679A (zh) 2022-06-14

Similar Documents

Publication Publication Date Title
BR112023018785A2 (pt) Composto cíclico fundido com pirimidina, método de preparação do mesmo e uso do mesmo
MX2025001810A (es) Compuestos que participan en la union cooperativa y usos de los mismos
BR112022008535A2 (pt) Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
WO2018136412A3 (en) Subcutaneous her2 antibody formulations
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
ES2723827T3 (es) Terapia de combinación de fármacos para el tratamiento de tumores sólidos
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112015025252A2 (pt) métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central